Local view for "http://purl.org/linkedpolitics/eu/plenary/2010-09-21-Speech-2-521"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2010-09-21"^^xsd:date2
dcterms:Is Part Of	lp_eu:Pharmacovigilance of medicinal products (amendment of Regulation (EC) No 726/2004) - Pharmacovigilance (amendment of Directive 2001/83/EC) (debate)2
dcterms:Language	"et"^^xsd:language2
lpv:document identification number	"en.20100921.18.2-521"2
lpv:hasSubsequent	lp_eu:2010-09-21-Speech-2-5222
lpv:speaker	lp:Siiri Oviir2
lpv:spokenAs	member; Delegation to the Euronest Parliamentary Assembly (2009-09-16--2014-06-30)3 substitute; Delegation to the EU-Armenia, EU-Azerbaijan and EU-Georgia Parliamentary Cooperation Committees (2009-09-16--2014-06-30)3 unknown; Eesti Keskerakond (2009-07-14--2012-05-24)3 member; EMPL (2009-07-16--2012-01-18)3 member_of_the_bureau; ALDE (2009-07-20--2014-06-30)3 member; FEMM (2009-07-16--2012-01-18)3 vice-chair; Delegation to the EU-Ukraine Parliamentary Cooperation Committee (2009-09-29--2014-06-30)3 substitute; ECON (2009-07-16--2011-06-21)3
lpv:translated text	"Pharmacovigilance has a very important position in public health. The side effects of medicines often have damaging effects on the health and lives of patients. Many legal cases have shown that pharmaceutical companies aim, for commercial reasons, to conceal the undesirable side effects of medicines for quite a long time. It is to be welcomed that, through adopting the proposed legislative acts, we will toughen up the criteria for ensuring the greater reliability of marketing authorisations or support the widespread use of the so-called emergency procedure. I support the measures for ensuring the quality of data in the pharmacovigilance system, and we should guarantee resources for efficient national pharmacovigilance. The whole system must be transparent for patients."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph